DiaGenic, Pfizer Sign Deal for Alzheimer's Biomarker Discovery

The firms will use DiaGenic's gene expression technology in a study to identify biomarkers related to patients who progress from mild cognitive impairment to Alzheimer's.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.